Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES AN EXTENSION OF ITS CONVERTIBLE DEBENTURES OFFERING

LSL Pharma Group Inc. has extended its brokered private placement, consisting of the issuance of unsecured convertible debentures at a price of $10 per debenture, until Feb. 7, 2024. As announced on Dec. 8, 2023, LSL Pharma Group has now raised total gross proceeds of $3,288,000 under the offering out of a maximum of $5-million (assuming the full exercise of the agent's option to increase the size of the offering by up to $1-million). The net proceeds of the offering will be used for working capital, capital expenditures and for general corporate purposes.

About LSL Pharma Group Inc.

LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high-quality sterile ophthalmic pharmaceutical products.

We seek Safe Harbor.